Evidence map›Paper›PMID 37400162›Full record

ArticleBMJ supportive & palliative care2023

Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu - a single-center randomised controlled trial.

Huifeng Gao, Jian He, Chien-Shan Cheng, Liping Zhuang, Hao Chen, Zhiqiang Meng

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ supportive & palliative care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01715532 (Phase II Study of Huachansu for Treatment of Advanced Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01715532 phase2unknown statusnot on this map

Phase II Study of Huachansu for Treatment of Advanced Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase

TypeinterventionalSponsorFudan UniversityRan2012 to 2016Enrolled120ConditionsCarcinoma, HepatocellularArmsHuachansu, TACE
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huifeng Gao *Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jian He *Department of Oncology, Nanchang University, Nanchang, China.
Chien-Shan ChengDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Liping ZhuangDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hao ChenDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhiqiang MengDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China mengshca@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7550-3129

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHuachansu, a Chinese medicine derived from the dried skin glands of toad venom, has been used in China since the 1970s to treat liver cancer. Transarterial chemoembolisation (TACE) is the standard of care for patients with unresectable hepatocellular carcinoma (HCC). This study evaluated the efficacy and safety of the combination of TACE and Huachansu in unresectable HCC.

methodsFrom September 2012 to September 2016, 120 patients diagnosed with unresectable HCC were prospectively enrolled. Patients were randomised at a 1:1 ratio into the combined treatment group (Huachansu-TACE) and the TACE treatment group. The primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS) and safety. The exploration outcome serum Na

resultsA total of 112 patients who completed the study were included in the analysis. PFS and OS were significantly better in the Huachansu-TACE group than in the TACE group (p=0.029 and p=0.025, respectively), with a median PFS of 6.8 and 5.3; and a median OS of 14.8 months and 10.7 months, respectively. Although no prognostic significance was found between the baseline NKA-low and NKA-high groups in the patients' OS (p=0.48), its changes after 3-month follow-up showed significant prognostic values, of which, were 8.5 months and 23.8 months, respectively (p<0.001). Treatment-related adverse events were comparable between groups.

conclusionsHuachansu-TACE is effective in prolonging the PFS and OS in patients with unresectable HCC. TRIAL REGISTRATION NUMBER: NCT01715532.

Indexed as

Clinical assessmentComplementary therapyLiver

Identifiers

PMID37400162
PMCPMC11671927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.